| Literature DB >> 29626088 |
Andrew N Wilkinson1,2, Kate H Gartlan1,2, Greg Kelly1, Luke D Samson1, Stuart D Olver1, Judy Avery1,3, Nienke Zomerdijk1,3, Siok-Keen Tey1,3, Jason S Lee1, Slavica Vuckovic1,2, Geoffrey R Hill4,2,3.
Abstract
IL-6 mediates broad physiological and pathological effects through its receptor signal transducing unit gp130. Due to the reportedly wide cellular expression of gp130, IL-6 is thought to signal ubiquitously via gp130 complex formation with membrane-bound IL-6Rα or soluble IL-6Rα. gp130 signaling primarily induces p-STAT3 and p-STAT1. In contrast to the previous dogma, we show in this article that circulating mouse and human granulocytes are unable to induce p-STAT3 or p-STAT1 after stimulation with IL-6 or an IL-6/soluble IL-6R complex. Furthermore, we demonstrate that this is due to a lack of gp130 expression on mouse and human granulocytes, despite their expression of membrane-bound IL-6R. Importantly, the absence of gp130 is not only a feature of mature granulocytes in healthy individuals, it is also observed after allogeneic stem cell transplantation. Moreover, granulocyte gp130 expression is lost during maturation, because granulocyte-monocyte progenitor cells express gp130 and respond to IL-6. Given that granulocytes constitute 50-70% of circulating leukocytes, this indicates a significantly smaller scope of IL-6 signaling than previously anticipated and has important implications for therapeutic IL-6 inhibition and the mechanisms of action thereof.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29626088 DOI: 10.4049/jimmunol.1701191
Source DB: PubMed Journal: J Immunol ISSN: 0022-1767 Impact factor: 5.422